Diligence memo · auto-generated · as of July 2, 2026

Rift Biotherapeutics, Inc.

Rift Biotherapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Rift Biotherapeutics, Inc. operates in Biotechnology, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Rift Biotherapeutics, Inc. has raised $2.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.1M on 2017-03-17.

Most recent recorded round closed around 2017-03-17.

Valuation (modeled)modeled

Provath models Rift Biotherapeutics, Inc. at approximately $95M (range $1.5M–$742M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.33× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era. Within the normal band (133% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 9.3 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 29% of Biotechnology peers (4293 compared).

Modeled value ranks above 58% of those peers.

Closest niche peers: Mimedx Group, Inc., Kenjockety Biotechnology, LLC, Helocyte, Inc., CytoDel, INC., Finch Therapeutics, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.